Australia's most trusted
source of pharma news
Saturday, 30 March 2024
Posted 1 July 2022 AM
Aussie researchers have slammed companies for moving a combination therapy into human clinical trials before performing "sophisticated" preclinical studies.
Ipsen and Calitheria Biosciences have both initiated clinical trials in the US of a combined therapy that involves a glutaminase inhibitor and a PD-1 inhibitor - either MSD's Keytruda or BMS's Opdivo - for patients with lung cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.